Adeno-Associated Virus Gene Therapy in a Sheep Model of Tay-Sachs Disease.
暂无分享,去创建一个
Douglas R Martin | T. Denney | R. Beyers | M. Sena-Esteves | A. Bradbury | N. Salibi | Amanda R Taylor | B. Whitlock | J. Sartin | D. R. Wilhite | Ashley N. Randle | Douglas R. Martin | R. Winter | Hector R Benatti | A. Wooldridge | H. Gray-Edwards | Stacy A. Maitland | Lauren E. Ellis | N. Cox | B. L. Brunson | J. A. Johnson | A. Randle | M. Hwang | Peter F Canning | Spencer M Hubbard | Matthew B Vogel | A. S. Gentry | M. Holland | Hector R. Benatti | H. Benatti | A. Taylor | Misako Hwang | Brandon L. Brunson | Jacob A. Johnson
[1] C. Tifft,et al. MRI/MRS as a surrogate marker for clinical progression in GM1 gangliosidosis , 2016, American journal of medical genetics. Part A.
[2] C. Vite,et al. Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] H. J. Baker,et al. Mucopolysaccharidosis-like phenotype in feline Sandhoff disease and partial correction after AAV gene therapy. , 2015, Molecular genetics and metabolism.
[4] Chunxing Yang,et al. A Single Injection of Recombinant Adeno-Associated Virus into the Lumbar Cistern Delivers Transgene Expression Throughout the Whole Spinal Cord , 2015, Molecular Neurobiology.
[5] Torben Schneider,et al. Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. , 2015, Brain : a journal of neurology.
[6] V. Haurigot,et al. Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy. , 2015, Human molecular genetics.
[7] David Hurlbut,et al. Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] H. J. Baker,et al. Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease , 2015, Experimental Neurology.
[9] H. J. Baker,et al. Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease , 2014, Gene Therapy.
[10] James M. Wilson,et al. Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[11] H. J. Baker,et al. Sustained Normalization of Neurological Disease after Intracranial Gene Therapy in a Feline Model , 2014, Science Translational Medicine.
[12] E. Ayuso,et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. , 2013, The Journal of clinical investigation.
[13] H. J. Baker,et al. Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[14] K. Bankiewicz,et al. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. , 2013, Human gene therapy.
[15] R. Samulski,et al. Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates , 2012, Gene Therapy.
[16] Seng H. Cheng,et al. Gene Transfer Corrects Acute GM2 Gangliosidosis-Potential Therapeutic Contribution of Perivascular Enzyme Flow. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] F. Eichler,et al. Natural History of Infantile GM2 Gangliosidosis , 2011, Pediatrics.
[18] B. C. Lewis,et al. Pathology of GM2 Gangliosidosis in Jacob Sheep , 2011, Veterinary pathology.
[19] J. Alroy,et al. Tay-Sachs disease in Jacob sheep. , 2010, Molecular genetics and metabolism.
[20] H. Miyajima,et al. Serial MR Imaging and 1H-MR Spectroscopy in Monozygotic Twins with Tay-Sachs Disease , 2008, Neuropediatrics.
[21] L. Bilaniuk,et al. Serial 1H-MRS in GM2 gangliosidoses , 2008, European Journal of Pediatrics.
[22] B. Banwell,et al. The Natural History of Juvenile or Subacute GM2 Gangliosidosis: 21 New Cases and Literature Review of 134 Previously Reported , 2006, Pediatrics.
[23] Seng H. Cheng,et al. Effective gene therapy in an authentic model of Tay-Sachs-related diseases , 2006, Proceedings of the National Academy of Sciences.
[24] B. Tatlı,et al. Proton MR spectroscopy in three children with Tay-Sachs disease , 2005, Pediatric Radiology.
[25] R. Cole,et al. Presence of an Unusual GM2 Derivative, Taurine-conjugated GM2, in Tay-Sachs Brain* , 2003, Journal of Biological Chemistry.
[26] F. Shic,et al. Reduced glutamate neurotransmission in patients with Alzheimer's disease–an in vivo 13C magnetic resonance spectroscopy study , 2003, Magnetic Resonance Materials in Physics, Biology and Medicine.
[27] P. Venugopalan,et al. Cardiac involvement in infantile Sandhoff disease , 2002, Journal of paediatrics and child health.
[28] P. Antuono,et al. Decreased glutamate + glutamine in Alzheimer’s disease detected in vivo with 1H-MRS at 0.5 T , 2001, Neurology.
[29] P. Meikle,et al. Prevalence of lysosomal storage disorders. , 1999, JAMA.
[30] J. Steiss,et al. Profile of electrodiagnostic abnormalities in cats with GM1 gangliosidosis. , 1997, American journal of veterinary research.
[31] T Ernst,et al. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. , 1997, Radiology.
[32] Michael P. McDonald,et al. Mouse models of Tay–Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism , 1995, Nature Genetics.
[33] M. Jendoubi,et al. In situ assessment of beta-hexosaminidase activity. , 1995, BioTechniques.
[34] M. Sims. Electrodiagnostic evaluation of auditory function. , 1988, The Veterinary clinics of North America. Small animal practice.
[35] H. J. Baker,et al. GM2 ganglioside lysosomal storage disease in cats with beta-hexosaminidase deficiency. , 1977, Science.
[36] J. Buchwald,et al. Far-field acoustic response: origins in the cat. , 1975, Science.
[37] J. Moller,et al. Cardiac involvement in Sandhoff's disease. Inborn error of glycosphingolipid metabolism. , 1974, The American journal of cardiology.
[38] Douglas R Martin,et al. AAV Gene Therapy Strategies for Lysosomal Storage Disorders with Central Nervous System Involvement , 2015 .
[39] A. Panigrahy,et al. Magnetic resonance spectroscopy in pediatric neuroradiology: clinical and research applications , 2009, Pediatric Radiology.
[40] S. Woolley,et al. Lateral Sclerosis , 2004 .
[41] N Hanai,et al. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. , 1996, Human molecular genetics.
[42] L. Svennerholm. Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. , 1957, Biochimica et biophysica acta.